TrialJournal of clinical pharmacology2016

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.

Alan J Xiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.